rs11209026

A relatively rare allele at SNP rs11209026, in the IL23R gene, appears to provide a fairly strong protective effect against the development of Crohn's disease in both Jewish and non-Jewish populations. Note that in this study the (A;A) and (A;G) genotypes were combined for statistical reasons (there were too few (A;A) individuals to study by themselves), so the risk is shown as equal for both. associated With Inflammatory Bowel Diseases but Not With Celiac Disease rs11209026 had a protective effect for IBD in the case-control analysis (odds ratio [OR] 0.19, 95% confidence interval [CI] 0.10-0.37, P= 6.6E-09). Both CD (OR 0.14, CI 0.06-0.37, P= 3.9E-07) and UC (OR 0.33, CI 0.15-0.73, P= 1.4E-03) were associated with IL23R. rs2241880 was associated with CD susceptibility (OR 1.36, CI 1.12-1.66, P= 0.0017). The population-attributable risk of carrying allele G is 0.24 and is 0.19 for homozygosity for allele G in CD. With reference to ankylosing spondylitis, the rs11209026(A) allele also has a protective effect. The odds ratio for carriers is 0.63 (p=2.8x10e-5) based on a large study of over 1,000 Caucasian patients.PMID 17952073, PMID 18037607 This SNP is also part of a haplotype with rs7530511 associated with psoriasis.. And in rs11209026 was also confirmed to be associated with psoriasis. significant associations with rs1004819, rs7517847, and rs11209026. Having any CARD15 variant was associated with a significant risk for CD (P < 0.0001). Replicated reduced risk for Crohn's disease and ulcerative colitis with rs11209026(A) allele in a study of Italian patients. A genome-wide association study using DNA samples from 1,052 individuals with ulcerative colitis and preexisting data from 2,571 controls, all of European ancestry, concluded that this SNP and several others were associated with altered risk for the disease.

A;A

Greatly decreased risk of Ankylosing Spondylitis (0.36x), Chron's Disease, Psoriasis, and Ulcerative Colitis. This is the extremely rare homozygous mutant version of the interleukin-23 (IL-23) receptor.

A;G

Substantially decreased risk of Ankylosing Spondylitis (0.6x), Chron's Disease (0.37x), Psoriasis (0.6x), and Ulcerative Colitis (0.59x). This is the rare version of the interleukin-23 (IL-23) receptor.

G;G

Almost everyone has this form, but it indicates a slightly higher risk of Ankylosing Spondylitis, Crohn's Disease (1.09x), Psoriasis (1.06x), and Ulcerative Colitis (1.06x). The risk is much greater than for the rare version. This is the interleukin-23 (IL-23) receptor. [[Media:http://www.the-rheumatologist.org/details/article/2528901/Neutralizing_IL-23_and_Its_Targets_May_Improve_Ankylosing_Spondylitis.html] Neutralizing IL-23 and Its Targets May Improve Ankylosing Spondylitis by Lara C. Pullen, PhD in The Rheumatologist newsmagazine ]